Plant factory: new resource for the productivity and diversity of human and veterinary vaccines
10.7774/cevr.2019.8.2.136
- Author:
Byoung Shik SHIM
1
;
Kee Jong HONG
;
Puna Maya MAHARJAN
;
Sunghwa CHOE
Author Information
1. G+FLAS Life Sciences, Seoul, Korea. Shchoe@snu.ac.kr
- Publication Type:Brief Communication
- Keywords:
Transgenic plants;
Vaccines;
Pharmaceuticals;
Antibodies
- MeSH:
Antibodies;
Efficiency;
Escherichia coli;
Humans;
Insects;
Plants;
Plants, Genetically Modified;
Protein Processing, Post-Translational;
Vaccination;
Vaccines;
Vaccines, Synthetic;
Yeasts
- From:Clinical and Experimental Vaccine Research
2019;8(2):136-139
- CountryRepublic of Korea
- Language:English
-
Abstract:
Vaccination is one of the most successful strategies to prevent diseases caused by pathogens. Although various expression systems including Escherichia coli, yeast, insect, and mammalian cells are currently used for producing many of vaccines, these conventional platforms have the limitation of post-translational modification, high cost, and expensive scalability. In this respect, the plant-based expression system has been considered as an attractive platform to produce recombinant vaccines due to fast, cost-effective and scalable production as well as safety. This review discusses the development of plant-derived vaccines and the current stage of plant-based expression system.
